Survey Reveals Financial Benefits for GLP-1 Users
A recent national survey conducted by Sunlight.com has brought exciting news for both health and finance enthusiasts. The study showed that Americans using GLP-1 medications, such as Ozempic and Wegovy, are not only shedding pounds but also experiencing significant reductions in their monthly food expenditures.
Key Findings of the Survey
The survey, which involved 1,200 participants currently using GLP-1 medications, was conducted in September 2025. One of the prominent findings revealed that users are saving an average of
$218 each month on food-related expenses, equating to nearly a
30% reduction in overall food spending.
Breakdown of Spending Changes
The change in spending was evident across various categories:
- - Grocery bills decreased from $351 to $282.
- - Spending on restaurants and bars went down from $183 to $127.
- - Purchases for fast food and snacks fell from $183 to $106.
- - Additionally, costs for diet programs dropped from $95 to $78.
- - Interestingly, fitness expenses remained relatively stable throughout this period.
These figures portray how adopting GLP-1 medications supports not only weight loss but also encourages more mindful and economically friendly eating habits.
Net Financial Gains
When the calculations consider the average out-of-pocket expense for GLP-1 prescriptions, which users reported at approximately
$176 monthly, the results still paint a favorable financial picture. After accounting for the cost of their medication, users averaged a net savings of
$42 each month, leading to over
$500 in annual savings.
It’s noteworthy that financial incentives played a key role in many users' decisions to start a GLP-1 regimen. The survey indicated that
one in three respondents factored potential savings into their choice to begin using these medications. This sentiment was particularly pronounced among
Gen Z adults, who frequently cited financial motivations alongside health improvements.
Expert Insights
Dr. Angela Tran noted the emergence of what she describes as the **